Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2000

View Archived Issues

Protein Design Labs enters patent license agreement with Merck KGaA

Vertex enters genomic and proteomic alliance with Harvard

Immunomedics overviews product pipeline

Inflazyme reports phase I results with IPL-576092; phase II to commence mid-year

Alteon initiates phase IIa clinical trial of ALT-711

U.S. and Brazilian researchers team up to design new ribonucleotide reductase inhibitors

Patient dosing begins in phase I clinical trial of Angiostatin protein

Anxiolytic-like effects demonstrated for human ORL1 receptor agonist

Medivir completes acquisition of Mimetrix

Novel copolymer adjuvant enhances flu vaccine efficacy and immunogenicity

Inhibitors of IL-5 production synthesized by Janssen

Vanguard Medica highlights product development efforts for year-end 1999

Pola focuses on development of antifungal agents

Japanese patent issued to Sumitomo for new ECE inhibitors

Novel DELTA-lactones with utility in inflammatory conditions disclosed by Inflazyme

Proteasome inhibitor proven to induce apoptosis and to exert antitumor activity in vivo

New hybrid polar differentiation-inducing agent pyroxamide progresses to clinical trials

Maxamine plus IFN-alpha yields up to 69% complete response in HCV

Enbrel recommended by FDA advisory committee for early RA

Japanese academic team describes new anticancer compound

Novel antimalarial drug candidate presented at scientific meeting

News from FASEB: TBC-1269 mechanism-of-action studies described

Novel method of controlling hypertension described at Experimental Biology

Opioid agonists for the prevention of myocardial ischemia

British investigators implicate endothelin in the pathophysiology of BPH

Bayer reports continued success in clinical studies evaluating Bay-38-9456 for ED

Potential antiatherogenic agent featured in two presentations at Experimental Biology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...